Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ascendis Pharma A/SASND · Entity 1628 | SVP & PAO | September 08, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ascendis Pharma A/S
Report date September 08, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-08 · Exercise / conversion · Acquired 3,000 · Balance 3,000 Row 2 · 2026-09-08 · Sale · Disposed 3,000 · Balance 0 |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $110.00 · Expires 2032-10-11 | Direct | 687 |
Reported balance
After 2026-09-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-08 · Exercise / conversion · Disposed 3,000 · Balance 687 F1: The warrants vested 25% on October 11, 2023 and thereafter in 36 equal monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: The warrants vested 25% on October 11, 2023 and thereafter in 36 equal monthly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 9, 2026 21:04 UTC | Ascendis Pharma A/S ASND · Entity 1628 | Exercise / conversionWarrants · Derivative | 3,000 | $0.00 Strike: $110.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000409 · form4.xml · derivative · entry 3 Bodenhoff Mads · CIK 0002014697 · SVP & PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 687 Underlying: Ordinary Shares · 3,000 shares Expires 2032-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The warrants vested 25% on October 11, 2023 and thereafter in 36 equal monthly installments. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 21:04 UTC | Ascendis Pharma A/S ASND · Entity 1628 | SaleOrdinary Shares | 3,000 | $270.19 | $810,570.00 |
DisclosureSEC source: 0001610717-26-000409 · form4.xml · nonDerivative · entry 2 Bodenhoff Mads · CIK 0002014697 · SVP & PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 21:04 UTC | Ascendis Pharma A/S ASND · Entity 1628 | Exercise / conversionOrdinary Shares | 3,000 | $110.00 | $330,000.00 |
DisclosureSEC source: 0001610717-26-000409 · form4.xml · nonDerivative · entry 1 Bodenhoff Mads · CIK 0002014697 · SVP & PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.